The future of hemostasis management. - Wikidata - wikimedia - TriplyDB

The future of hemostasis management.

The future of hemostasis management.

http://www.wikidata.org/entity/Q38056457

about

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

P2860

Q38951490-DDED2FD4-70FA-4890-B58C-13FCFED28654 Q45864199-F3883122-ADE6-489E-B797-43ACECD55145

P2860

The future of hemostasis management.

http://www.wikidata.org/entity/Q38056457

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The future of hemostasis management.

@en

type

label

The future of hemostasis management.

@en

prefLabel

The future of hemostasis management.

@en

P1433

Q38056457-7835BCB7-5ECA-44F7-806E-99CFE39276EA

P1476

Q38056457-F05C356F-0590-4526-ADEA-465BF21C3C1F

P2093

Q38056457-4BB290E2-81D0-4CBC-8B66-198854C403F3

P2860

Q38056457-0A71C91E-2BA5-4E69-8F57-6A9639B9D9CB

Q38056457-0B0BF254-E98E-4125-ACA1-1A0BF8401F82

Q38056457-260FC727-2EA8-4C33-92AE-C0E661C52D33

Q38056457-3CF872E6-B5F1-4444-B421-318566496CDB

Q38056457-4023B1DE-E10B-4005-88CB-69F59B568BC9

Q38056457-46862DF9-8927-4AB9-AEEB-D3B4C37684D4

Q38056457-6C299B24-F08E-4703-86FF-E89613B628DD

Q38056457-73C5EA1D-CCC4-41B9-9D1A-AAC99420839A

Q38056457-78E6F316-0B26-45A4-97A1-B83552EF81BC

Q38056457-81C6BCF8-4A61-4476-A532-EB477F7B0063

P304

Q38056457-A627976C-98AB-4ACF-9450-DF547F4DBEBE

P31

Q38056457-EB7A5E7E-E781-4F6A-A480-CF633BC3A9E5

P356

Q38056457-95A569BF-32DA-4B07-BF57-E3F6823E4EFE

P478

Q38056457-B71BF450-1EA8-4A6E-864E-A01E70638800

P577

Q38056457-67B5FB87-7F11-429D-9D28-C79A6DB647D2

P698

Q38056457-72CC5C17-20CE-4489-8F45-E3C88578F0AE

P356

P1433

Pediatric Blood & Cancer

P1476

The future of hemostasis management.

@en

P2093

David Lillicrap

http://www.w3.org/2001/XMLSchema#string

P2860

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Control of bleeding in patients with haemophilia A with inhibitors: a systematic review.

Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.

450 million years of hemostasis.

A brief historical review of the waterfall/cascade of blood coagulation.

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.

Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

Gene therapy in haemophilia--going for cure?

P304

S44-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24334

http://www.w3.org/2001/XMLSchema#string

P478

60 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23109347

http://www.w3.org/2001/XMLSchema#string